Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade

RecruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
AML (Acute Myelogenous Leukemia)
Interventions
BIOLOGICAL

Laboratory tests and in vitro studies

Cell models, co-culture condition set-up and functional validation, Single-cell RNA sequencing and NGS, Metabolomics analysis, metabolomics validation and intracellular metabolomics analysis, Metabolic ImmunoProfiling and epigenetic profile, CyTOF immune and signaling profiling, Monocyte, macrophages and MSCs in vitro assays.

Trial Locations (1)

40138

RECRUITING

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna

All Listed Sponsors
lead

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER